New authorized medicine: VIZIMPRO (dacomitinib)

5 juin 2019

BlueReg

VIZIMPRO (dacomitinib) is a cancer medicine used to treat adults with non-small cell lung cancer (NSCLC) when the disease is advanced or has spread. Vizimpro is used on its own and only in patients with certain mutations (changes) in the gene for a protein called epidermal growth factor receptor (EGFR).

BlueReg

Vous avez aimé cet article ? Partagez le sur les réseaux sociaux :

Découvrez notre dernier livre blanc

En savoir plus